Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02680977 : Mucuna Pruriens Therapy in Parkinson's Disease
PhasePhase 2
AgesMin: 21 Years Max: N/A
Inclusion Criteria:

- Clinical diagnosis of idiopathic Parkinson's disease according to the United Kingdom
Brain Bank criteria, defined by the presence of at least two of the cardinal signs of
the disease (resting tremor, bradykinesia, rigidity) without any other known cause of

- Sustained response to levodopa and presence of motor fluctuations for at least 1 h
every day during waking hours, defined as predictable wearing-off, unpredictable
ON-OFF fluctuations and sudden OFF periods.

- Patients had to receive optimum LD+DDCI, be stable for at least 30 days before
baseline assessment.

- Availability to written informed consent

Exclusion Criteria:

- Cognitive impairment according to Mini-Mental State Examination < 26/30

- Clinically significant psychiatric illness, including psychosis, major depression and
addiction disorders (including compulsive levodopa intake).

- Hoehn and Yahr stage of 5/5 in the medication-OFF state

- Severe, unstable medical conditions (i.e. unstable diabetes mellitus, moderate to
severe renal or hepatic impairment, neoplasms)

- Risk of pregnancy
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557